MetLife Investment Management’s Enliven Therapeutics ELVN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $425K | Sell |
21,211
-258
| -1% | -$5.18K | ﹤0.01% | 1760 |
|
|
2025
Q1 | $423K | Sell |
21,469
-277
| -1% | -$5.45K | ﹤0.01% | 1808 |
|
|
2024
Q4 | $489K | Buy |
21,746
+1,285
| +6% | +$28.9K | ﹤0.01% | 1816 |
|
|
2024
Q3 | $523K | Hold |
20,461
| – | – | ﹤0.01% | 1761 |
|
|
2024
Q2 | $478K | Buy |
20,461
+8,116
| +66% | +$190K | ﹤0.01% | 1737 |
|
|
2024
Q1 | $217K | Hold |
12,345
| – | – | ﹤0.01% | 2162 |
|
|
2023
Q4 | $171K | Hold |
12,345
| – | – | ﹤0.01% | 2327 |
|
|
2023
Q3 | $169K | Hold |
12,345
| – | – | ﹤0.01% | 2302 |
|
|
2023
Q2 | $252K | Buy |
+12,345
| New | +$252K | ﹤0.01% | 2134 |
|